News | June 16, 2025
AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
AstraZeneca Pharma India discontinues manufacturing of Imdur
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Subscribe To Our Newsletter & Stay Updated
